Omalizumab: as the comparator
26 studies: what is tested is compared with it. Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 AntihistaminesNot yet recruitingNCT07946913Phase 3How we knowReport a problem
- A Study to Find a Suitable Dose of Exl-111 for Further ResearchRecruitingNCT07356713Phase 1How we knowReport a problem
- Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma PatientsRecruitingNCT07342803Phase 2How we knowReport a problem
- Trial of JYB1904 in Chronic Spontaneous Urticaria.RecruitingNCT06509334Phase 2How we knowReport a problem
- Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic UrticariaCompletedNCT04976192Phase 3Results postedHow we knowReport a problem
- Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous UrticariaCompletedNCT04833855Phase 2Results postedHow we knowReport a problem
- A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistaminesCompletedNCT03580369Phase 3Results postedHow we knowReport a problem
- A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.CompletedNCT03580356Phase 3Results postedHow we knowReport a problem
- Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSUCompletedNCT02477332Phase 2Results postedHow we knowReport a problem
- Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With AsthmaCompletedNCT01716754Phase 2Results postedHow we knowReport a problem
- A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mLCompletedNCT01544348Phase 1Results postedHow we knowReport a problem
- Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male SubjectsCompletedNCT07246252Phase 1How we knowReport a problem
- A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy VolunteersCompletedNCT06494345Phase 1How we knowReport a problem
- Trial of JYB1904 in Patients With Allergic AsthmaCompletedNCT06438757Phase 2How we knowReport a problem
- To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous UrticariaCompletedNCT06365879Phase 3How we knowReport a problem
- Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) TreatmentCompletedNCT06228560Phase 2How we knowReport a problem
- Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.Active, not recruitingNCT06042478Phase 3How we knowReport a problem
- A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic DiseasesCompletedNCT05960708Phase 1How we knowReport a problem
- The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and ImmunogenicityCompletedNCT05897008Phase 1How we knowReport a problem
- A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic DiseasesCompletedNCT05564221Phase 1How we knowReport a problem
- Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese SubjectsCompletedNCT05449535Phase 1How we knowReport a problem
- To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy SubjectsCompletedNCT05413161Phase 1How we knowReport a problem
- A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic DiseasesCompletedNCT05061524Phase 1How we knowReport a problem
- An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial AsthmaCompletedNCT04607629Phase 3How we knowReport a problem
- Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single InjectionTerminatedNCT04361812Phase 1How we knowReport a problem
- A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic AsthmaCompletedNCT01703312Phase 1/2How we knowReport a problem